Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenith Drugs's Total Assets for the quarter that ended in Mar. 2026 was ₹1,875 Mil.
Warning Sign:
If a company builds assets at 33.3% a year, faster than its revenue growth rate of 17% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Zenith Drugs's average Total Assets Growth Rate was 18.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 25.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 33.30% per year.
During the past 6 years, Zenith Drugs's highest 3-Year average Total Assets Growth Rate was 39.90%. The lowest was 25.70%. And the median was 34.20%.
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Zenith Drugs's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Zenith Drugs Total Assets Related Terms
Zenith Drugs Total Assets Historical Data
* Premium members only.
The historical data trend for Zenith Drugs's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Zenith Drugs's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenith Drugs (NSE:ZENITHDRUG) has a Total Assets of ₹1,875 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Zenith Drugs and its competitors.
Is Zenith Drugs' Total Assets too high?
Zenith Drugs' current Total Assets is ₹1,875 Mil. Overall, Zenith Drugs has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' Total Assets compare to ZTS and UTHR?
Zenith Drugs' Total Assets of ₹1,875 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Zenith Drugs and its competitors. Zenith Drugs's current Total Assets is ₹1,875 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current Total Assets of ₹1,875 Mil. The current Total Assets is ₹1,875 Mil. Zenith Drugs' overall GF Score™ is 36/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current Total Assets is ₹1,875 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
36GF Score
Get the complete analysis for NSE:ZENITHDRUG
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZENITHDRUG has been successfully added to your 
